← Leaderboards
Zhengqiang Wang
University Of Minnesota
$10,211,439
Attributed
$20,411,493
Total exposure
8
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,411,493 · 8
By mechanism
R01$19,301,658 · 6
U01$713,862 · 1
R21$395,973 · 1
Top collaborators
- Stefan G Sarafianos30 shared
- Robert James Geraghty5 shared
- Michael A Parniak4 shared
- Zhilong Yang2 shared
- Jiashu Xie1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Erik T Yukl$2,308,453
- Amer Alam$2,122,232
- Ryan Langlois$16,405,551
- William Arndt$93,005
- Jiashu Xie$197,987
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceAnalogCellsVirusStructureMolecularLeadAntiviral AgentsDesignProteinsDrug ResistanceBiochemicalVirologyBaseViralBindingInnovationPharmaceutical PreparationsDrug KineticsIn VivoPublishingPharmaceutical ChemistryReverse TranscriptionMutation
Grant awards (39)
Development of novel antivirals against mpox (monkeypox) virus$767,359
R01 · FY2025 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$695,135
R01 · FY2025 · AI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$526,582
R01 · FY2025 · AI
Development of deazaflavin analogs as potent and selective MRP1 inhibitors for cancer chemosensitization$395,973
R21 · FY2025 · CA
Development of novel antivirals against mpox (monkeypox) virus$783,602
R01 · FY2024 · AI · contact PI
Discovery of SARS-CoV-2 antivirals using a replicon assay$678,703
R01 · FY2024 · AI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$530,513
R01 · FY2024 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay$75,307
R01 · FY2024 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay$13,952
R01 · FY2024 · AI
Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning$713,862
U01 · FY2023 · NS · contact PI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein$654,500
R01 · FY2023 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay$643,490
R01 · FY2023 · AI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$534,364
R01 · FY2023 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay$657,615
R01 · FY2022 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein$654,500
R01 · FY2022 · AI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$538,140
R01 · FY2022 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein$654,500
R01 · FY2021 · AI
Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles$551,383
R01 · FY2021 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein$654,500
R01 · FY2020 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$568,676
R01 · FY2020 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein$654,500
R01 · FY2019 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$579,866
R01 · FY2019 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$446,402
R01 · FY2019 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$590,494
R01 · FY2018 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$438,413
R01 · FY2018 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$425,333
R01 · FY2017 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$384,959
R01 · FY2017 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$220,564
R01 · FY2017 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$160,502
R01 · FY2017 · AI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$749,422
R01 · FY2016 · AI
Taking aim at HBV eradication using novel NRTIs and Capsid effectors$617,972
R01 · FY2016 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$511,509
R01 · FY2016 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$13,841
R01 · FY2016 · AI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$751,724
R01 · FY2015 · AI
Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals$465,907
R01 · FY2015 · AI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$748,607
R01 · FY2014 · AI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$4,564
R01 · FY2014 · AI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$643,710
R01 · FY2013 · AI
Novel antivirals targeting the RNase H activity of HIV reverse transcriptase$710,548
R01 · FY2012 · AI